Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
8,708 total articles
Dorman Products (DORM) trades at a reasonable multiple given $75.7M of free cash flow, a $3.34B market cap and low leverage. Management changes and a steady pipeline of first-to-aftermarket parts reduce execution risk. I see an asymmetric mid-term trade ahead of Q1 earnings: buy into strength with a clear stop and a target near prior resistance.
Shell’s reported $16 billion ARC transaction tightens the landscape for high-quality upstream assets and supports a re-rating for low-cost natural gas producers. With crude trading above $100 and macro risk pushing energy real assets back into favor, Tourmaline stands out as a pragmatic trade: strong free-cash-flow potential, domestic LNG optionali…
Pulse Seismic should benefit from higher oil prices and an uptick in Western Canadian exploration activity. This trade seeks to capture a mid-term rebound driven by stronger seismic demand, with a clear entry at $2.40, target of $3.60 and a protective stop at $1.80.
AppLovin remains a top adtech growth name supported by AI-driven ad products and strong recent growth prints. The stock has pulled back from short-term overbought levels; technicals and short-interest dynamics favor a tactical long. This trade idea outlines a mid-term swing to capture continued monetization gains while limiting downside with a tigh…
Nucor (NUE) is trading near $222 after a year of volatility and operational execution that highlights the advantages of its mini-mill model and capital discipline. With a market cap around $50.6B, a manageable debt load (debt-to-equity ~0.34) and EPS of $7.63, the company looks set to convert cyclical upside into sustained shareholder returns. This…
Kiniksa (KNSA) just raised full-year Arcalyst guidance after Q1 revenue of $214M and is trading near a 52-week high. The earnings beat, strong free cash flow and an active clinical pipeline create a favorable setup for a long trade. This idea outlines an entry at current levels, a protective stop and a 180-trading-day target tied to continued uptak…
Stride’s platform issues appear to be fading and enrollment updates are broadly constructive. At roughly a $4.1B market cap and an EV/EBITDA near 7.2, the stock is priced for modest growth. We present a mid-term long trade that bets on re-rating as enrollment stabilizes and guidance holds.
Roivant's Genevant settlement with Moderna and a string of positive Phase 3 results for brepocitinib give the company both near-term optionality and a path to sustainable revenue. With $9.73 billion in reported cash, a market cap near $19.8 billion and a pipeline catalyst calendar through 2026, ROIV is a buy for patient, risk-tolerant investors tar…
Starbucks delivered a punchy Q2 with $9.5B in revenue and comps beating expectations. The market has been overly obsessed with headline multiples; underlying cash flow, margin recovery and restored U.S. traffic suggest upside in the next 45 trading days. This trade isolates momentum while protecting capital with a clear stop.
POET Technologies rocketed and then crashed after Marvell canceled orders tied to Celestial AI and multiple law firms opened investigations. At $6.51 and a ~$995M market cap, the company is now priced for a worst-case near-term outcome. That creates a tactical mid-term (45 trading days) long opportunity for disciplined traders who accept headline r…
Pollard Banknote is a small-cap, cash-generative printer of lottery and secure products. Recent margin compression appears cyclical and tied to temporarily elevated input and logistics costs plus mix shifts. With cost actions in place and a steady backlog of contracted work, the stock looks like a high-probability margin-recovery trade. This note l…
Connect Biopharma (CNTB) is a small-cap clinical-stage biotech whose IL-4Rα antibody rademikibart has shown efficacy in type 2 asthma. With presentations supporting lung function gains and reduced exacerbations, there's a plausible extension into an emergency/acute-exacerbation setting. At a market cap near $142M and enterprise value near $97M, thi…
Adobe trades around $243 with a roughly $98 billion market cap, attractive cash generation and a 25% buyback authorization. Those positives mask growing AI-driven product risk and deteriorating technical support near the 50-day EMA. We outline a mid-term short with clear entry, stop and target and a balanced risk framework.
Coupang (CPNG) is recovering from headline risk and is now showing the early benefits of heavy infrastructure and AI investment. At a $37.2B market cap and roughly 1.1x revenue, the stock looks positioned for a mid-term rebound as revenue growth resumes and operating leverage from logistics and AI kicks in. This trade idea outlines a specific entry…
Western Digital is trading well above its prior highs after a torrid run driven by AI data-center demand and industry supply constraints. Fundamentals - including $2.3B in annual free cash flow, a $132.6B market cap and strong ROE - back a continuation thesis. This trade idea lays out an entry at $410.00, a stop at $360.00 and a mid-term target of …
NGL Energy Partners hit a 52-week high and is trading on improving crude fundamentals, stronger cash generation and visible logistics contracts. The balance of valuation (EV/EBITDA ~7.2), positive free cash flow and elevated short interest create an asymmetric trade opportunity. We favor a disciplined long with defined entry, stop and targets over …
UMB Financial (UMBF) is showing accelerating technical and fundamental momentum after recent quarters of acquisitive growth. With P/E near 14, a 1.3% dividend yield, and a conservative balance sheet, the risk/reward looks favorable for a mid-term long trade targeting the 52-week high at $136.11. We lay out an entry, stop and target and explain the …
Clorox (CLX) trades on a sensible P/E, yields ~5%, and is grappling with a temporary retailer inventory reset. With a market cap near $11.7B and free cash flow of $778M, the risk/reward favors a mid-term swing long if management executes margin recovery and consumption stabilizes. Entry $96.60, stop $88.00, target $115.00 for a 45-trading-day trade…
Nike is trading near its recent low with RSI in the high-30s, positive MACD momentum, and a 3.6% dividend yield. The combination of attractive yield, improving category trends and a tight short-interest backdrop make a controlled long trade appealing: entry $45.00, stop $41.50, target $52.00 over a mid-term (45 trading days) horizon.
Nvidia's datacenter dominance and software stack are re-pricing the company's earnings trajectory away from a classic semiconductor cycle. With a $5.24 trillion market cap, 79%+ revenue growth expected into May earnings, and blockbuster free cash flow, this is a trade to own into AI infrastructure momentum — if you accept near-term volatility from …
Alaska Air (ALK) reported a Q1 loss and warned of roughly $600 million of extra fuel cost pressure for Q2. The shares are trading near $40 with negative free cash flow, elevated leverage and a stretched current ratio. With crude prices and geopolitical risk still the dominant driver, this is a trade to sell the bounce: entry $40.00, stop $44.00, ta…
Smurfit-WestRock (WRK) is my favorite long-term pick right now. The combination of scale, structural demand for sustainable packaging, and the ability to drive synergies make this a compelling risk-reward into the next 6-9 months. This trade plan lays out a concrete entry, stop and target with catalysts and what would change my view.
Doximity (DOCS) has been punished by headline risk and a software selloff even as its physician network and high margins remain intact. Trading near $24.57 and a market cap around $4.6B, DOCS offers a favorable risk/reward for a mid-term swing: entry at $24.57, stop at $20.55, target $36.00 over ~45 trading days.
Aktis Oncology is a clinical-stage radiopharmaceutical company with a deep-pocketed IPO and a pipeline built around miniprotein radioconjugates designed to reach large patient populations. Recent IND clearance activity and first clinical imaging/dosimetry data for AKY-2519 set up a series of binary catalysts. At a market cap near $990M and with ~ $…
Joby Aviation is a pure-play eVTOL with clear commercialization milestones — NYC demo flights and a confirmed Dubai launch in 2026 — but the balance sheet, negative cash flow and a premium valuation make shares a speculative long. Buy on a measured pullback, size tightly, and treat this as a catalyst-driven swing trade: certification, early revenue…
